You just read:

U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer

News provided by

Daiichi Sankyo Company, Limited

Dec 01, 2016, 08:00 ET